I respectfully disagree. $5.1 million now. Minimal outgoing cost...

I respectfully disagree.
$5.1 million now. Minimal outgoing cost until trial commencement possibly in Q420 which will coincide with an additional $2.9 million.

With this $8 million it would be safe to say that ACW will go it alone on MCI. It has already been suggested that Edinburgh will cover Diabetes. I speculate that there is another undisclosed university that is running our mysterious fourth trial, further speculation that this is paid for also (Bill eluded to this in a presentation late last year - I think). That leaves Schizophrenia unpaid for. Grants and collaborations aren't unlikely based on Xanamem's reliable data set of safety, efficacy and occupancy.

If we do manage to spend $6 million between now and July 21 then we will also receive an additional rebate in Q4 of circa $2.8 million. Leaving us with $4-5 million left for H2 2021.

Without non-dilutive funds you are right though, we will require funding for the ambitious quantity of trials at some point mid-late 2021 as I have said before. However I would suspect that having 2-4 trials well underway would present us with a healthy share price resulting in minimal dilution. We may even have results back from a shorter trial prior to needing more funds. this is wishful thinking though.

A bit of perspective on share price being to high. There is just 2, possibly even 1 (if we get a breakthrough des) good trial result that stands between Actinogen and >$13 billion US/year. A gamble no doubt. But if the Casino had odds this good I would probably go more often.

Disclaimer: This is a lot of speculation. They could capital raise tomorrow and dilute us by 30% again for all I know. This level of stupidity would be out of character though.